Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

ÀüÀ̼º Àü¸³¼±¾Ï¿¡¼­ÀÇ ³²¼ºÈ£¸£¸ó ¼ö¿ëü¿Í ¼¼Æ÷°í»ç¹ßÇö¿¡ °üÇÑ ¿¬±¸ Study on Expressions of Androgen Receptor and Apoptosis In Human Metastatic Prostate Adenocarclnoma

´ëÇѺñ´¢±â°úÇÐȸÁö 1999³â 40±Ç 3È£ p.332 ~ 340
Á¤µµ¿µ, Á¶ÀçÈï,
¼Ò¼Ó »ó¼¼Á¤º¸
Á¤µµ¿µ (  ) 
¾ÆÁÖ´ëÇб³ ÀÇ°ú´ëÇÐ ÀÀ±ÞÀÇÇб³½Ç

Á¶ÀçÈï (  ) 
°í·Á´ëÇб³ ÀÇ°ú´ëÇÐ ºñ´¢±â°úÇб³½Ç

Abstract

°á·Ð
1989³âºÎÅÍ 1994³â±îÁö °í·Á´ëÇÐ ÀÇ·á¿ø ºñ´¢±â°ú¿¡ ÀÔ¿øÇÏ¿© Áø´Ü¹ÞÀº Á¤»óÀü¸³¼±±º 5
·Ê, Àü¸³¼±ºñ´ëÁõ±º 16·Ê¿Í ³»ºÐºñ¿ä¹ý ÀüÀÇ ÀüÀ̼º Àü¸³¼±¾Ï±º 31·Ê¿¡¼­ ¼¼Æ÷°í»ç¿Í ³²¼º
È£¸£¸ó ¼ö¿ëü¿¡ ´ëÇÑ ¸é¿ªÁ¶Á÷ È­ÇÐÀû ¾ç¼º¹ßÇöÀÇ °á°ú¸¦ ºÐ¼®ÇÏ¿© ´ÙÀ½°ú °°Àº °á·ÐÀ» ¾ò
À» ¼ö ÀÖ¾ú´Ù. ³²¼ºÈ£¸£¸ó ¼ö¿ëü¿Í ¼¼Æ÷°í»ç¹ßÇöµµ°£ÀÇ »ó°ü¼º °Ë»ç¿¡¼­ Á¤»óÀü¸³¼±°ú Àü
¸³¼±ºñ´ëÁõÀº ºñ·Ï Åë°èÇÐÀûÀ¸·Î À¯ÀÇÇÏÁö´Â ¾Ê¾ÒÀ¸³ª ³ôÀº ¹Ýºñ·ÊÀÇ »ó°ü¼ºÀÌ °üÂûµÇ¾ú´Ù
´Â Á¡¿¡¼­ ³²¼ºÈ£¸£¸ó ¼ö¿ëüÀÇ Àü¸³¼±ÀÇ »ýÈ­ÇÐÀû ¼º»ó°£ÀÇ ¿¬°ü¼ºÀÌ ½Ã»çµÇ¾ú´Ù. ±×·¯³ª
³»ºÐºñ¿ä¹ý ÀüÀÇ ÀüÀ̼º Àü¸³¼±¾Ï¿¡¼­´Â ³²¼ºÈ£¸£¸ó ¼ö¿ëüÀÇ ¾ç¼º¹ßÇöÀÌ Á¶Á÷ÇÐÀûÀ¸·Î Ư
¡ÀÌ ¾ø°í ¼¼Æ÷°í»ç¹ßÇöµµ¿Íµµ »ó°ü¼ºÀÌ ¾ø¾úÀ¸¸ç, »ýÁ¸À² °Ë»ç¿¡¼­µµ Àǹ̰¡ ¾ø¾ú´Ù´Â Á¡
¿¡¼­ ³²¼ºÈ£¸£¸ó ¼ö¿ëüÀÇ ¹ßÇö¿©ºÎ·Î Àü¸³¼±¾ÏÀÇ ³²¼ºÈ£¸£¸ó ÀÇÁ¸¿¡ ´ëÇÑ ÀÌÁú¼ºÀ» ¿¹ÃøÇÏ
±â¿¡´Â ÀûÇÕÇÏÁö ¾Ê¾Ò´Ù. ±×·¯³ª Àü¸³¼±¾Ï¿¡¼­ ¼¼Æ÷°í»çÀÇ ¹ßÇöÀÌ Á¤»óÁ¶Á÷°ú Àü¸³¼± ºñ´ë
Áõ°ú´Â ´Þ¸® ¾ç¼º°ú À½¼ºÀÇ ÆíÀçÇö»óÀÌ °üÂûµÇ°í, À½¼ºÀÇ ÆíÀçºóµµ´Â ³ª»Û ºÐÈ­µµÀϼö·Ï ÀÚ
ÁÖ °üÂûµÇ¸ç, ³²¼ºÈ£¸£¸ó ¼ö¿ëü¿Í´Â »ó°ü°ü°è°¡ ¾ø´Â Á¡ ±×¸®°í ³»ºÐºñ¿ä¹ý ÈÄÀÇ »ýÁ¸À²ÀÌ
Àú¾ç¼º ¹ßÇöÀ²±º¿¡¼­ ºÒ·®Çß´Ù´Â Á¡ µî¿¡¼­, ÀüÀ̼º Àü¸³¼º¾ÏÀÇ ÀÌÁú¼º ÆÇ´Ü¿¡ ¼¼Æ÷°í»ç¹ß
ÇöÀ²ÀÇ Æò°¡´Â Àǹ̰¡ ÀÖ´Ù°í ÆǴܵǾú´Ù. µû¶ó¼­ ÇâÈÄ ¼¼Æ÷°í»ç¹ßÇö¾ç»óÀÇ º¯È­¿¡ µû¸¥ °´
°üÀûÀÎ Æò°¡ÀÇ ±âÁؼ³Á¤°ú ÇÔ²² Àü¸³¼±¾ÏÀÇ ÀÌÁú¼ºÀÇ Á¤È®ÇÑ ±Ô¸íÀ» À§ÇÏ¿© ¼¼Æ÷ÀÇ Áõ½Ä ¹×
¼Ò¸ê°úÁ¤¿¡ °ü¿©ÇÏ´Â ¿ä¼Ò¿¡ ´ëÇÑ Àû±ØÀûÀÎ ¿¬±¸°¡ ÇÊ¿äÇÏ´Ù°í »ý°¢µÈ´Ù.

Purpose: Study on expressions of androgen receptor(AR) and apoptosis in metastatic
prostate cancer before antiandrogen therapy may give rise to clue informations that
could enable to predict the heterogeneity of androgen dependence.
Materials and Methods: With paraffin blocks of metastatic prostate cancer(n=31),
benign prostate hyperplasia(n=16) and normal prostate(n=5), characteristics of apoptosis
positivity and nuclear androgen repceptor expression were evaluated. Prostate cancers
were also grouped by Gleason sum into group ¥° (well differentiated; n=7), ¥±
(moderately differentiated; n=9) and ¥²(poorly differentiated; n=15). Apoptosis was
expressed by in-situ hybridization technique and AR was evlauated by
immunohistochemical method.
Results: Study with statistics of median positive rate of apoptosis and AR among
three groups, revealed no relationship between expression of apoptosis and AR
(correlation coefficient: CE=-0.523, p=0.362 in normal: CE=-0.406, p=0.119 in BPH;
CE=-0.022, p=0.905 in cancer). Also there was no correlation between expression of
apoptosis and AR in subgroups of cancer. In log-rank survival test, survivals according
to the expression of apoptosis showed good survival rate in group of high
positive(p=0.013), whereas study of AR showed no significant findings. Histologic
findings of apoptotic cell in cancer were different from that of normal and BPH, which
distributions of apoptotic cells were even in normal and BPH, but in cancer, these were
uneven and collected patterns, which might mean the cell collections of androgen
dependent or not.
Conclusions: Good survival in group of high posive apoptosis and eleven collections of
apoptotic cells in cancer may have important implications for solving the problems that
could predict the heterogeneity of androgen dependence in prostate cancer before
antiandrogen therapy, although study of AR is not sufficient to predict the heterogeneity
of prostate cancer.

Å°¿öµå

Prostate cancer; Androgen receptor; Apoptosis;

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

   

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS